Share

September 13, 2016; 87 (11) Article

Incidence of subarachnoid hemorrhage is decreasing together with decreasing smoking rates

Miikka Korja, Hanna Lehto, Seppo Juvela, Jaakko Kaprio
First published August 12, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003091
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
425

Share

Article Information

vol. 87 no. 11 1118-1123
DOI: 
https://doi.org/10.1212/WNL.0000000000003091
PubMed: 
27521438
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received December 26, 2015
  • Accepted in final form April 14, 2016
  • First Published August 12, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Miikka Korja, MD, PhD,
    2. Hanna Lehto, MD, PhD,
    3. Seppo Juvela, MD, PhD and
    4. Jaakko Kaprio, MD, PhD
  1. Miikka Korja, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Hanna Lehto, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Maire Taposen s??ti? (Maire Taponen Foundation) 1500e 2. Emil Aaltosen s??ti? (Emil Aaltonen Foundation) 5000e

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Seppo Juvela, MD, PhD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1) Associate editor: European Journal of Neurology, 2007-- ; 2) Editorial board member: Stroke, 2005--

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jaakko Kaprio, MD, PhD
    5. Scientific Advisory Boards:

    1. D-tect project, PI professor Berit Heitmann, Copenhagen University, non-profit

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Pfizer Ltd, speaker honorarium 2012

    Editorial Boards:

    1. Addiction, associate editor, 2008 - > Nicotine and Tobacco Research, associate editor, 2010 - > Twin Research and Human Genetics, editorial board member, 2003 -> Finnish Journal of Social Medicine 2000-> Psychiatric Genetics, editorial board member 2000->

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Pfizer Ltd, Pharmacogenetics of smoking cessation, 2011-2014

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1.  Addiction program (#118555, PI) 2007-2010 Academy of Finland, Centre of Excellence in Complex Disease Genetics, J.Kaprio group 2006-2011 Academy of Finland Finnish Distinguished Professor programme, co-host for Professor Joe Terwilliger (Columbia University) 2006-2010 Academy of Finland Finnish Distinguished Professor programme, host for Professor Juni Palmgren (Karolinska Institute) 2011-2015 Academy of Finland. Genes and environmental predictors of tobacco addiction in adolescents and young adults (PI). Consortium partner Olli Raitakari, University of Turku. Co-funded with CIHR (PI Rachel Tyndale, University of Toronto) . Funded through the SKIDI-Kids Research program. 2011-2014 European Union funding EC FP6. DiOGenes. Diet, Obesity and Genes. FP6-513946. J.Kaprio PI for University of Helsinki, http://www.diogenes-eu.org/ 2005-2009 EC FP7. TORNADO. Molecular Targets Open for Regulation by the gut flora ? New Avenues for improved Diet to Optimize European health. KBBE-2007-2-2-07/222720-2 (JK PI for University of Helsinki partner, WP leader) Integrating project http://www.fp7tornado.eu/ 2009-2013 EC FP7. ENGAGE Consortium European Network for Genetic and Genomic Epidemiology. (HEALTH-F4-2007-201413). (JK PI University of Helsinki, University of Helsinki coordinator partner, JK WP leader). http://www.euengage.org/ Integrating project 2008-2012 EC FP7. GENODISC (Disc-degeneration linked pathologies: novel biomarkers and diagnostics for targeting treatment and repair). HEALTH-F2-2008-201626. 1.3.08-28.2.13. J.Kaprio PI for Helsinki partner and WP leader. (http://www.physiol.ox.ac.uk/genodisc/index.html) 2008-2013 EC FP7 I.Family. Determinants of eating behaviour in European children, adolescents and their parents-KBBE-2010-4. 2012-2017. J. Kaprio PI for University of Helsinki partner. 2012-2017 US NIH funding U.S. -P.H.S. (# DA-12584, yrs 6-10). Nicotine addiction genetics. Co-PI J.Kaprio. Finnish subcontract 2008-2012 U.S. -P.H.S. (# AA-12502) FinnTwin12 studies of alcohol use. Co-PI J.Kaprio. Finnish subcontract 2005-2010 U.S. -P.H.S. (# AA-15416, PI DM Dick) Gene-environment interactions in adolescent alcohol use. J.Kaprio Co-Investigator, 2005-2010 U.S.-P.H.S. (#AA-15416, PI DM Dick, Virginia Commonwealth University), supplemental award for genotyping 2009-2011 U.S.-P-H.S (# HL104125, Xiaoling Wang, Medical College of Georgia. A genome-wide methylation study on essential hypertension. (local PI J Kaprio) 2011-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurosurgery (M.K., H.L.), University of Helsinki and Helsinki University Hospital; Departments of Clinical Neurosciences (S.J.) and Public Health (J.K.), University of Helsinki; Department of Health (J.K.), National Institute for Health and Welfare; and Institute for Molecular Medicine FIMM (J.K.), Helsinki, Finland.
  1. Correspondence to Dr. Korja: miikka.korja{at}hus.fi
View Full Text

Article usage

Article usage: August 2016 to July 2022

AbstractFullPdfSource
Aug 20162545030Highwire
Sep 201619761435Highwire
Oct 2016338610Highwire
Nov 201621535Highwire
Dec 201614227Highwire
Jan 201711213Highwire
Feb 20177413Highwire
Mar 20178223Highwire
Apr 20176735Highwire
May 20174923Highwire
Jun 20174311Highwire
Jul 20177875Highwire
Aug 20175924Highwire
Sep 201719811Highwire
Sep 2017978pmc
Oct 20176334Highwire
Oct 20176109pmc
Nov 20173212Highwire
Nov 201792025pmc
Dec 20173306Highwire
Jan 20189517Highwire
Feb 20185345Highwire
Mar 20185115Highwire
Apr 20185748Highwire
Apr 201831819pmc
May 201845213Highwire
Jun 20187405Highwire
Jun 201811415pmc
Jul 201813315Highwire
Aug 201867110Highwire
Aug 201811922pmc
Sep 20185121Highwire
Oct 201863314Highwire
Nov 20188437Highwire
Dec 20186424Highwire
Jan 20192824Highwire
Feb 20194226Highwire
Mar 20194907Highwire
Apr 201939110Highwire
May 201945010Highwire
Jun 20196316Highwire
Jul 20193202Highwire
Aug 20191913Highwire
Sep 20192112Highwire
Oct 20195024Highwire
Nov 201951314Highwire
Dec 20197703Highwire
Jan 20205813Highwire
Feb 20204763Highwire
Mar 20204510Highwire
Apr 20204342Highwire
May 20205303Highwire
Jun 20204422Highwire
Jul 20203500Highwire
Aug 20203300Highwire
Sep 20204711Highwire
Oct 20207110Highwire
Nov 20208142Highwire
Dec 20205231Highwire
Jan 20215612Highwire
Feb 20215143Highwire
Mar 20217421Highwire
Apr 20215300Highwire
May 20216587Highwire
Jun 20216721Highwire
Jul 20214520Highwire
Aug 20218010Highwire
Sep 20215222Highwire
Oct 20215900Highwire
Nov 20215221Highwire
Dec 20216311Highwire
Jan 20225311Highwire
Feb 20226212Highwire
Mar 20228311Highwire
Apr 20226452Highwire
May 20227411Highwire
Jun 20224000Highwire
Jul 20224223Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me